Ind-Swift Laboratories Limited has submitted its latest investor presentation to stock exchanges on January 14, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The comprehensive presentation outlines the company's strategic transformation and future growth trajectory following a historic business restructuring.

Strategic Transformation Overview

The company has successfully completed a strategic reset through the ₹1,650 crore divestment of its API & CRAMS business to Synthimed Labs Pvt. Ltd., a portfolio company of India Resurgence Fund (Bain Capital & Piramal). This decisive action has transformed the company into a net debt-free entity with a unified operational structure.

The merger of Ind-Swift Limited into Ind-Swift Laboratories Limited, effective March 31, 2024 and NCLT-approved, has created a single, streamlined, formulation-focused listed entity. The company now operates as a pure-play Finished Dosage Formulation (FDF) platform with a solid revenue base of ₹550 crores.

Business Operations and Infrastructure

Post-transformation, the company operates through two primary divisions. The International Division (Global Business Unit) maintains presence across 85+ countries with strong CMO relationships and regulated market penetration, supported by an extensive dossier pipeline. The Domestic Division covers Ethical, Generics, P2P and other segments through 260+ marketing teams covering 20,000 retailers and 25,000+ doctors.

Financial Performance and Growth Targets

The company reported steady performance in the first half of FY26. Total income increased from ₹167.32 crores in Q1 FY26 to ₹170.50 crores in Q2 FY26, representing a 1.91% growth. EBITDA improved from ₹18.18 crores to ₹19.34 crores, with EBITDA margins expanding by 47 basis points to 11.34%.

The company targets sustained expansion to double revenue by FY29, supported by high-margin segments including Ethical (76% gross margin), Own-Brand (51% gross margin) and CMO (42% gross margin). Management expects topline CAGR of 20-25%, scaling from ₹550 crores to ₹1,200+ crores by FY29.

Product Portfolio and Market Presence

The company maintains a diversified export portfolio with Fexofenadine contributing 22% of product revenue, followed by Atorvastatin at 13% and Metformin at 7%. The company has filed 1,915+ dossiers across 85+ countries with 520+ approvals received, demonstrating strong regulatory capabilities.

Upcoming product launches include partnerships with Viatris for commercial supplies starting FY27, expected to generate ₹200 crore incremental revenue impact. The pipeline includes Ibuprofen Sachet, Clarithromycin Dry Suspension, and Esomeprazole formulations across European and Australian markets.

Leadership and Strategic Vision

Chairman and Managing Director N.R. Munjal emphasized the company's transformation: "The restructuring has consolidated our capabilities across manufacturing, R&D and distribution, positioning the entire organization for scalable, capital-efficient growth. We are accelerating execution across high-growth engines by strengthening CDMO visibility through the FY27 accretive Viatriis partnership."

The presentation, available on the company's website at www.indswiftlabs.com , provides comprehensive details on the company's evolution from a diversified pharmaceutical entity to a focused formulations platform positioned for sustained growth in global markets.

Ind-Swift Laboratories Limited has filed a regulatory disclosure under SEBI SAST regulations on December 18, 2025, regarding the completion of share transmission to the legal heirs of Late Mrs. Neera Mehta.

Share Transmission Details

The company transmitted 2,32,057 equity shares to the joint demat account of three legal heirs of Late Mrs. Neera Mehta. These shares were previously pending credit due to regulatory approvals required for the amalgamation of Ind-Swift Limited with Ind-Swift Laboratories Limited.

Regulatory Compliance

The transmission was completed under the exemption available under Regulation 10(1)(g) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation provides exemption for transmission of shares to legal heirs upon demise of a shareholder.

Rishav Mehta, acting as a Promoter and on behalf of the legal heirs, submitted the disclosure to both BSE Limited and National Stock Exchange of India Limited. The company confirmed that there is no change in the aggregate shareholding of the Promoters and Promoter Group following this transmission.

Shareholding Structure Post-Transaction

The post-transaction shareholding details reveal the distribution among the legal heirs:

The joint holding increased from 2,49,000 shares (0.31%) to 4,81,057 shares (0.59%) following the transmission of the remaining shares from Late Mrs. Neera Mehta's holding. The entire shareholding of Late Mrs. Neera Mehta has now been fully transmitted to the joint account of her legal heirs by way of transmission.

Filing Documentation

The disclosure was filed in compliance with Regulation 10(6) of the SEBI SAST Regulations, with all required details submitted to the stock exchanges. The filing includes comprehensive shareholding details and confirms that the transmission was completed relying upon the exemption available under the regulations for inter-se transfer of shares between promoters of the company.